SWI/SNF-Compromised Cancers Are Susceptible to Bromodomain Inhibitors
Tatiana Shorstova1, Maud Marques1, Jie Su1
1Departments of Oncology and Experimental Medicine, McGill University, Lady Davis Institute and Segal Cancer Centre, Jewish General Hospital, Montreal, Quebec, Canada.
Abstract:
The antitumor activity of bromodomain and extraterminal motif protein inhibitors (BETi) has been demonstrated across numerous types of cancer. As such, these inhibitors are currently undergoing widespread clinical evaluation. However, predictive biomarkers allowing the stratification of tumors into responders and nonresponders to BETi are lacking. Here, we showed significant antiproliferative effects of low dosage BETi in vitro and in vivo against aggressive ovarian and lung cancer models lacking SMARCA4 and SMARCA2, key components of SWI/SNF chromatin remodeling complexes. Restoration of SMARCA4 or SMARCA2 promoted resistance to BETi in these models and, conversely, knockdown of SMARCA4 sensitized resistant cells to BETi. Transcriptomic analysis revealed that exposure to BETi potently downregulated a network of genes involved in receptor tyrosine kinase (RTK) signaling in SMARCA4/A2-deficient cells, including the oncogenic RTK HER3. Repression of signaling downstream of HER3 was found to be an important determinant of response to BETi in SMARCA4/A2-deficient cells. Overall, we propose that BETi represent a rational therapeutic strategy in poor-prognosis, SMARCA4/A2-deficient cancers. SIGNIFICANCE: These findings address an unmet clinical need by identifying loss of SMARCA4/A2 as biomarkers of hypersensitivity to BETi.
Insights
Loss of SMARCA4/A2 predicts sensitivity to bromodomain and extraterminal motif protein inhibitors (BETi) in aggressive ovarian and lung cancers. These findings identify potential biomarkers for BET inhibitor therapy.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Therapeutics
Background:
- Bromodomain and extraterminal motif protein inhibitors (BETi) show antitumor activity but lack predictive biomarkers for patient stratification.
- SWI/SNF chromatin remodeling complexes, including SMARCA4 and SMARCA2, are crucial in cancer development.
Purpose of the Study:
- To investigate the therapeutic potential of BET inhibitors in aggressive cancers lacking SMARCA4 and SMARCA2.
- To identify predictive biomarkers for response to BET inhibitors.
Main Methods:
- In vitro and in vivo antiproliferative assays using ovarian and lung cancer models.
- Genetic manipulation (restoration and knockdown) of SMARCA4 and SMARCA2.
- Transcriptomic analysis to identify molecular pathways affected by BET inhibitors.
Main Results:
- Low-dose BET inhibitors demonstrated significant antiproliferative effects in SMARCA4/A2-deficient cancer models.
- Restoration of SMARCA4/A2 conferred resistance to BET inhibitors, while knockdown sensitized resistant cells.
- BET inhibitors downregulated receptor tyrosine kinase (RTK) signaling, including HER3, in deficient cells, which determined response.
Conclusions:
- Loss of SMARCA4/A2 identifies tumors hypersensitive to BET inhibitors.
- BET inhibitors represent a rational therapeutic strategy for poor-prognosis SMARCA4/A2-deficient cancers.
- SMARCA4/A2 deficiency serves as a predictive biomarker for BET inhibitor efficacy.
Related Concept Videos
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Magnetic Susceptibility and Permeability
When diamagnetic materials are placed under an external magnetic field, the moments opposite to the field are induced. Hence, the susceptibility for diamagnets has a minimal negative value of 10-5–10-6. Since...
Susceptibility, Permittivity and Dielectric Constant
Dipeptidyl Peptidase 4 Inhibitors
Antihypertensive Drugs: Direct Renin Inhibitors
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors


